

PTO-1449 REPRODUCED SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION August 23, 2005 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3890.1000-000		APPLICATION NO. 10/528,250	
	FIRST NAMED INVENTOR Malcolm Carter		FILING DATE June 21, 2005	
	EXAMINER	CONFIRMATION NO.	GROUP	

U.S. PATENT DOCUMENTS				
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
/BK/	A1	5,776,930	07-07-1998	Lynch, Jr., <i>et al.</i>
↓	A2	6,436,971 B2	08-20-2002	DeMarsh, <i>et al.</i>
↓	A3	5,593,988	01-14-1997	Tahara, <i>et al.</i>
↓	A4	5,218,114	06-08-1993	Bock, <i>et al.</i>
↓	A5	5,220,018	06-15-1993	Bock, <i>et al.</i>
↓	A6	4,988,692	01-19-1991	Gasc, <i>et al.</i>
	A7			
	A8			
	A9			
	A10			
	A11			
	A12			
	A13			
	A14			
	A15			
	A16			
	A17			
	A18			
	A19			
	A20			
	A21			
	A22			
	A23			
	A24			
	A25			

EXAMINER /Bruck Kifle/ (08/29/2007)	DATE CONSIDERED 08/29/2007
--	-------------------------------

PTO-1449 REPRODUCED SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION August 23, 2005 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3890.1000-000	APPLICATION NO. 10/528,250	
	FIRST NAMED INVENTOR Malcolm Carter		FILING DATE June 21, 2005
	EXAMINER	CONFIRMATION NO.	GROUP

FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO	
/BK/	B1	EP 0 167 919 A2	01-15-1986	Merck & Co., Inc.		
	B2	EP 0 434 364 A2	06-26-1991	Merck & Co., Inc.		
	B3	EP 0 475 231 A1	03-18-1992	F. Hoffmann-La Roche AG		
	B4	EP 0 508 797 A1	10-14-1992	Merck & Co., Inc.		
	B5	EP 0 508 798 A1	10-14-1992	Merck & Co., Inc.		
	B6	EP 0 523 845 A2	01-20-1993	Merck & Co., Inc.		
	B7	WO 98/18473	05-07-1998	Merck & Co., Inc.		
	B8	CN1338456	03-06-2002	Ins. of Medical Materials Chin (CN)	(abstract only)	
	B7	WO 00/28947	05-25-2000	Sanofi-Synthelabo	abstract	
	B10	WO 99/19306	04-22-1999	Board of Regents, The University of Texas System		
	B12	KR212435	08-02-1999	Korea Res Inst Chem Tech (KR)		
	B12	WO 98/00406	01-08-1998	Merck & Co., Inc.		
	B13	WO 95/14470	06-01-1995	Merck & Co., Inc.		
	B14	WO 93/11771	06-24-1993	Cocensys, Inc.		
	B15	WO 93/07129	04-15-1993	Yoshitomi Pharmaceutical Industries, Ltd.	(abstract only)	
	B16	EP 0 421 802 A2	04-10-1991	Merck & Co., Inc.		
	B17	EP 0 284 256 A1	09-28-1988	Merck & Co., Inc.		
	B18	WO 00/66106	11-09-2000	The Regents of the University of Michigan		
	B19	JP 02-215774	08-28-1990	Roussel Uclaf	abstract	
	B20	EP 0 638 560 A1	02-15-1995	Yoshitomi Pharmaceutical Industries, Ltd.		
↓	B21	WO 02/40023 A1	05-23-2002	SmithKline Beecham Corporation		

EXAMINER /Bruck Kifle/ (08/29/2007)	DATE CONSIDERED 08/29/2007
--	-------------------------------

PTO-1449 REPRODUCED SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION August 23, 2005 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3890.1000-000		APPLICATION NO. 10/528,250	
	FIRST NAMED INVENTOR Malcolm Carter		FILING DATE June 21, 2005	
	EXAMINER	CONFIRMATION NO.	GROUP	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
/BK/	C1	Del Giudice, <i>et al.</i> , Chemical Abstract 97:23755 CA, "Synthesis of 2- and 3-amino-1, 4-benzodiazepines," <i>Farmaco, Edizione Scientifica</i> 37(5):434-452 (1982).
/BK/	C2	Kelsey, R., et al., "Synthesis, Resolution and Evaluation of Small Molecule Inhibitors of Respiratory Syncytial Virus," Presented at 44 th ICAAC, Oct. 30-Nov 2, 2004.
	C4	
	C4	
	C5	
	C6	
	C7	
	C8	
	C9	
	C10	
	C11	
	C12	
	C13	
	C14	
	C15	

EXAMINER /Bruck Kifle/ (08/29/2007)	DATE CONSIDERED 08/29/2007
--	-------------------------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION March 16, 2005 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3890.1000-000	APPLICATION NO. 10/528250	
	FIRST NAMED INVENTOR Malcolm Carter		FILING DATE
	EXAMINER	CONFIRMATION NO.	GROUP

FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO	
/BK/	AL	WO 01/74783 A1	10-11-01	Dupont Pharmaceuticals Company		
	AM	WO 00/66106 A2	11-09-00	The Regents of the University of Michigan		
	AN	WO 01/00611 A1	01-04-01	Janssen Pharmaceutica N.V.		
	AO	EP 0491218 A1	06-24-92	F. Hoffmann-LaRoche AG		
	AP	WO 00/12547 A1	03-09-00	Innogenetics N.V.		
	AQ	WO 01/92235 A1	12-06-01	Dupont Pharmaceuticals Company		
	AL2	WO 95/14471 A1	06-01-95	Merck & Co., Inc.		
	AM2	WO 93/17011 A1	09-2-93	Merck Sharp & Dohme		
↓	AN2	WO 01/90084 A1	11-29-01	Merck Sharp & Dohme Limited		
	AQ2					
	AP2					
	AQ2					
	AL3					
	AM3					
	AN3					
	AO4					
	AP3					
	AQ3					
	AL4					
	AM4					
	AN4					
	AO4					
	AP4					
	AQ4					

EXAMINER /Bruck Kifle/ (08/29/2007)	DATE CONSIDERED 08/29/2007
--	-------------------------------



Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete If Known		
			Application Number	10/528,250-Conf. #2767	
			Filing Date	June 21, 2005	
			First Named Inventor	Malcolm CARTER	
			Art Unit	1624	
			Examiner Name	B. Kifle	
Sheet	1	of	1	Attorney Docket Number	NV2-023US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
/BK/	A1*	US-5,719,143	02-17-1998	Badorc et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with a single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IPW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Bruck Kifle/ (08/29/2007)	Date Considered	08/29/2007
-----------------------	----------------------------	--------------------	------------